RA CAPITAL MANAGEMENT, L.P.
Q4 2020 13F-HR Holdings
Net value change ($000)
+1,686,364
(30.8%)
New positions
22
Sold out positions
11
Turnover %
23.0%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q3 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| NVAX | 292,594 | 225.3% |
| ARVN | 225,220 | 259.7% |
| AVIR | 224,294 | NEW |
| TGTX | 215,638 | 91.3% |
| NKTX | 176,057 | 104.5% |
| Kinnate Biopharma Inc. | 142,932 | NEW |
| TVTX | 124,225 | NEW |
| RCKT | 117,143 | NEW |
| OLMA | 103,391 | NEW |
| ImmunoGen, Inc. | 93,447 | 368.7% |
Top Reduces (Value $000, Stocks/ETFs)
| PCVX | -162,322 | -62.2% |
| Forma Therapeutics Holdings, Inc. | -134,634 | -30.0% |
| MCRB | -134,473 | -100.0% |
| Eidos Therapeutics, Inc. | -109,310 | -100.0% |
| TVTX | -85,575 | -100.0% |
| ADAPY | -76,940 | -85.1% |
| VXRT | -56,235 | -78.2% |
| RLMD | -29,392 | -100.0% |
| CRNX | -28,532 | -78.2% |
| Prevail Therapeutics Inc. | -19,500 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|